## Windlas Biotech Ltd: Comprehensive Financial Analysis

**1. Company Overview:**

Windlas Biotech Ltd. is an Indian pharmaceutical company operating in the Pharmaceuticals - Indian - Formulations industry.  Its core business is as a contract development and manufacturing organization (CDMO), specializing in the production of solid and liquid dosage forms for generic pharmaceuticals, including complex generics.  The company holds a strong market position, ranking among the top five domestic CDMOs in India based on revenue.  While specific notable achievements aren't detailed in the provided data, its consistent growth and market position suggest a successful track record.

**2. Key Financial Metrics:**

* **Current Price:** ₹ 1,032
* **P/E Ratio:** 35.2
* **Return on Equity (ROE):** 13.7% (TTM)
* **Return on Capital Employed (ROCE):** 18.2% (TTM)
* **Dividend Yield:** 0.53%
* **Market Capitalization:** ₹ 2,156 Cr.
* **Book Value:** ₹ 225
* **Debt-to-Equity Ratio:**  Not available in the provided data.  Further analysis is needed to calculate this crucial metric.


**3. Strengths and Weaknesses:**

**Strengths:**

* **Strong Growth:**  The company exhibits robust sales and profit growth, particularly in the last 3 years (14% and 23% CAGR respectively) and TTM (25% and 31% CAGR respectively).
* **Healthy ROCE:**  A ROCE of 18.2% indicates efficient utilization of capital.
* **Relatively Low Debt:** The "Other Insights" section mentions the company is "almost debt free," although this needs verification through a detailed analysis of the debt-to-equity ratio.
* **Consistent Dividend Payout:**  Maintaining a dividend payout suggests profitability and a commitment to shareholder returns.
* **Improved Working Capital Management:**  Reduction in working capital days from 65.3 to 32.8 days demonstrates improved operational efficiency.

**Weaknesses:**

* **High P/E Ratio:** A P/E ratio of 35.2 is relatively high compared to some peers, suggesting the stock might be overvalued or that the market anticipates significant future growth.
* **ROE Needs Scrutiny:** While the TTM ROE is 13.7%, the 3-year average is lower (12%), indicating potential variability in profitability.
* **Missing Debt-to-Equity Ratio:** The absence of this crucial metric hinders a complete assessment of the company's financial risk profile.
* **Data Gaps:**  The provided data contains several null values (e.g., 10-year growth rates, some annual tax percentages), limiting the scope of a comprehensive analysis.


**4. Performance Trends:**

* **Quarterly Results:** Sales and profits show a generally upward trend, although there's some quarterly fluctuation. Operating profit margins remain relatively stable around 11-12%.
* **Annual Results:**  Significant year-on-year growth in sales and net profit is evident, although there's considerable volatility in some years (e.g., the exceptionally high EPS in FY2022).
* **Balance Sheet Health:**  The balance sheet shows increasing reserves and assets, suggesting growth and financial stability. However, a detailed analysis of liquidity ratios is needed.
* **Cash Flow Trends:**  Cash flow from operating activities is generally positive, but investing activities show significant negative cash flows in some years, potentially indicating substantial capital expenditures.
* **Financial Ratios:**  The provided ratios (debtor days, inventory days, etc.) show some variability, requiring further analysis to assess their implications for operational efficiency.


**5. Growth Metrics:**

* **Sales CAGR:** 15% (5 years), 14% (3 years), 25% (TTM)
* **Profit CAGR:** 21% (5 years), 23% (3 years), 31% (TTM)
* **Stock Price CAGR:** 57% (3 years), 141% (1 year)
* **ROE:** 12% (5 years), 12% (3 years), 14% (Last Year), 10-year data unavailable.

The growth rates are impressive, particularly the TTM figures, suggesting strong momentum. However, the lack of 10-year data limits the long-term perspective.


**6. Comparison to Benchmarks:**

Windlas Biotech's P/E ratio (35.2) is relatively lower than some peers but higher than the median (36.33).  Its ROCE (18.2%) is also competitive but below the highest performers.  Market capitalization is significantly smaller than its peers.  A more detailed comparison requires a deeper dive into profitability, efficiency, and growth potential relative to each peer's specific business model and market segment.


**7. Stock Valuation:**

Based on the available data, a definitive valuation is challenging. The high P/E ratio suggests potential overvaluation, especially considering the relatively lower ROE compared to some peers.  However, the strong growth rates and relatively low debt (if confirmed) could justify a premium valuation.  A thorough discounted cash flow (DCF) analysis and a more detailed comparison with peers are necessary for a precise valuation.  The Price-to-Book ratio (1032/225 = 4.6) is also high, suggesting potential overvaluation.


**8. Recommendations and Confidence Levels:**

* **Short-term (3-6 months):** Hold.  The recent strong growth might continue, but the high valuation and market volatility warrant caution.  **Confidence Level: Medium.**
* **Medium-term (6-12 months):**  Hold or cautiously buy on dips.  Continued strong performance could justify the current valuation, but risks remain.  **Confidence Level: Medium.**
* **Long-term (1+ years):**  Buy.  The company's growth potential in the Indian pharmaceutical CDMO sector is promising.  However, this recommendation hinges on further investigation into the company's debt levels and a more robust valuation analysis.  **Confidence Level: Medium.**


**9. Final Verdict:**

Windlas Biotech exhibits strong growth potential, particularly in the short to medium term. However, the high P/E ratio and limited data (especially regarding debt and long-term trends) introduce significant uncertainty.  Before making any investment decisions, investors should conduct thorough due diligence, including:

* **Obtain a complete financial statement analysis:** This should include calculating the debt-to-equity ratio, liquidity ratios, and profitability ratios over a longer time horizon.
* **Perform a comprehensive peer comparison:**  A detailed comparison with competitors will provide a clearer picture of Windlas Biotech's competitive advantages and valuation.
* **Conduct a robust valuation:**  A DCF analysis and other valuation models are crucial to determine whether the current price reflects the company's intrinsic value.

Only after addressing these data gaps and conducting a more thorough analysis can a higher confidence level be assigned to investment recommendations.  The current analysis suggests a cautiously optimistic outlook, but further investigation is essential.
